Dr. Michael Recht entered the role of Chief Medical and Scientific Officer at the foundation in early 2023.
Prior to this role, he served as the Chief Science Officer (CSO) of the American Thrombosis and Hemostasis Network (ATHN). As ATHN's CSO, Dr. Recht worked at the strategic and policy level to inform the scientific direction of the organization.
In addition to his role as ATHN's CSO, Dr. Recht, a pediatric hematologist and Professor of Clinical Pediatrics at Yale University School of Medicine, sees children and young adults affected by non-malignant blood conditions, particularly bleeding and clotting disorders. As a member of the Division of Pediatric Hematology/Oncology, he contributes to the care of children with blood disorders at Yale New Haven Children's Hospital.
Before assuming his role as ATHN's CSO, Dr. Recht was previously the director of the Hemophilia Center at Oregon Health & Science University in Portland, OR as well as the director of the Mountain States Hemophilia Network, the federally-supported collaboration of Hemophilia Treatment Centers in the states of Alaska, Arizona, Colorado, Idaho, Montana, New Mexico, Oregon, Utah, Washington and Wyoming.
Dr. Recht has actively participated in over 110 clinical research trials testing new treatments for children with bleeding and clotting disorders, including being a leader in research involving gene therapy for hemophilia.